TheraVet SA (ALVET.PA)
EUR 0.11
(-0.46%)
EUR 0.11
(-0.46%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.64 Million EUR | -99.59% |
| 2022 | 1.78 Million EUR | 58.52% |
| 2021 | 1.12 Million EUR | 289.4% |
| 2020 | 288.99 Thousand EUR | 201.63% |
| 2019 | 95.81 Thousand EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 330.05 Thousand EUR | 0.0% |
| 2024 Q1 | 330.05 Thousand EUR | 83.33% |
| 2023 Q2 | 748.69 Thousand EUR | 111.3% |
| 2023 Q1 | 354.32 Thousand EUR | 335.96% |
| 2023 Q4 | 180.02 Thousand EUR | -61.52% |
| 2023 Q3 | 467.83 Thousand EUR | -37.51% |
| 2023 FY | 7226.00 EUR | -99.59% |
| 2022 Q1 | 305.47 Thousand EUR | -64.89% |
| 2022 Q3 | 362.98 Thousand EUR | 351.47% |
| 2022 Q4 | 81.27 Thousand EUR | -77.61% |
| 2022 FY | 1.78 Million EUR | 58.52% |
| 2022 Q2 | -144.34 Thousand EUR | -147.25% |
| 2021 Q1 | 175.75 Thousand EUR | -63.79% |
| 2021 Q3 | 247.88 Thousand EUR | 123.28% |
| 2021 Q2 | -1.06 Million EUR | -705.93% |
| 2021 FY | 1.12 Million EUR | 289.4% |
| 2021 Q4 | 869.94 Thousand EUR | 250.94% |
| 2020 Q4 | 485.4 Thousand EUR | 447.79% |
| 2020 Q3 | 88.61 Thousand EUR | -36.15% |
| 2020 Q2 | 138.78 Thousand EUR | 219.23% |
| 2020 FY | 288.99 Thousand EUR | 201.63% |
| 2020 Q1 | 43.47 Thousand EUR | 0.0% |
| 2019 FY | 95.81 Thousand EUR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| ABIONYX Pharma SA | 4.17 Million EUR | 60.634% |
| ABIVAX Société Anonyme | 127.37 Million EUR | 98.709% |
| Adocia SA | 15.62 Million EUR | 89.479% |
| Aelis Farma SA | 18.81 Million EUR | 91.262% |
| Biophytis S.A. | 14.33 Million EUR | 88.528% |
| Advicenne S.A. | 8.21 Million EUR | 79.984% |
| genOway Société anonyme | 16.73 Million EUR | 90.176% |
| IntegraGen SA | 5.35 Million EUR | 69.28% |
| Medesis Pharma S.A. | 1.56 Million EUR | -5.097% |
| Neovacs S.A. | 10.34 Million EUR | 84.103% |
| NFL Biosciences SA | 4.37 Million EUR | 62.41% |
| Plant Advanced Technologies SA | 2.76 Million EUR | 40.528% |
| Quantum Genomics Société Anonyme | 1.71 Million EUR | 4.287% |
| Sensorion SA | 27.05 Million EUR | 93.922% |
| Theranexus Société Anonyme | 3 Million EUR | 45.281% |
| TME Pharma N.V. | 5.49 Million EUR | 70.087% |
| Valbiotis SA | 9.86 Million EUR | 83.339% |
| Valerio Therapeutics Société anonyme | 20.32 Million EUR | 91.908% |
| argenx SE | 1.34 Billion EUR | 99.878% |
| BioSenic S.A. | 7.58 Million EUR | 78.316% |
| Celyad Oncology SA | 8.49 Million EUR | 80.632% |
| DBV Technologies S.A. | 89.4 Million EUR | 98.161% |
| Galapagos NV | 327.98 Million EUR | 99.499% |
| Genfit S.A. | 54.8 Million EUR | 97.0% |
| GeNeuro SA | 14.35 Million EUR | 88.547% |
| Hyloris Pharmaceuticals SA | 17.98 Million EUR | 90.858% |
| Innate Pharma S.A. | 64.57 Million EUR | 97.453% |
| Inventiva S.A. | 120.18 Million EUR | 98.632% |
| MaaT Pharma SA | 21.59 Million EUR | 92.387% |
| MedinCell S.A. | 32.92 Million EUR | 95.005% |
| Nanobiotix S.A. | 58.92 Million EUR | 97.21% |
| Onward Medical N.V. | 20.64 Million EUR | 92.035% |
| Oryzon Genomics S.A. | 18.49 Million EUR | 91.11% |
| OSE Immunotherapeutics SA | 23.58 Million EUR | 93.029% |
| Oxurion NV | 12.21 Million EUR | 86.537% |
| Pharming Group N.V. | 204.24 Million EUR | 99.195% |
| Poxel S.A. | 28.76 Million EUR | 94.284% |
| GenSight Biologics S.A. | 32.66 Million EUR | 94.965% |
| Transgene SA | 31.23 Million EUR | 94.735% |
| Financière de Tubize SA | 114.38 Thousand EUR | -1337.475% |
| UCB SA | 2.94 Billion EUR | 99.944% |
| Valneva SE | 134.92 Million EUR | 98.781% |
| Vivoryon Therapeutics N.V. | 24.69 Million EUR | 93.341% |